La psychothérapie assistée par la MDMA dans la prise en charge du syndrome de stress post-traumatique
Baptiste Fauvel, Pascale Piolino
Psychologie Francaise June 29, 2021 DOI: 10.1016/j.psfr.2020.12.003 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | MDMA |
| Topics | MDMA |
| Key points | The text states that PTSD remains chronic and severe for 25 to 50 percent of patients despite psychotherapy, and that phase II trial results confirm MDMA improves psychotherapy for PTSD without serious side effects, with phase III trials underway. It notes that MAPS has published a protocol and trains therapists, and that the FDA and EMA may authorize MDMA-assisted psychotherapy in coming years. |
Abstract
Resume On estime que le syndrome de stress post-traumatique (PTSD) reste chronique et severe pour 25 a 50 % des patients malgre une prise en charge psychotherapeutique. La MDMA (« ecstasy ») possederait des proprietes psychopharmacologiques qui renforcent l’alliance therapeutique et permettent au patient de travailler sur le contenu traumatique sans etre submerge par la peur et l’anxiete. Les resultats d’essais cliniques de phase II confirment que la MDMA ameliore efficacement la prise en charge psychotherapeutique des patients atteints de PTSD sans effets secondaires serieux. Des essais de phases III sont en cours. La Multidisciplinary Association for Psychedelic Studies (MAPS) a mis en ligne une proposition de methode et forme des therapeutes pour mener des psychotherapies assistees par la MDMA. La Food and Drug Administration (FDA) et l’European Medicines Agency (EMA) pourraient autoriser cet outil therapeutique dans les prochaines annees.
Citations in the library
Cites 50
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Journal of Psychopharmacology October 31, 2012
- MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology September 1, 2019
and 45 more in the library